Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer

•Oxaliplatin (OXA) is a third-generation platinum anti-cancer agent that is commonly used to treat colorectal cancer (CRC).•A number of molecular factors, non-coding RNAs, and signaling pathways have been implicated in OXA resistance in CRC cells.•Several anti-tumor compounds and nanoparticles have shown promise in enhancing OXA sensitivity and reversing OXA resistance in CRC.•This review article provides a comprehensive overview of the molecular mechanisms of OXA resistance in CRC and the potential strategies for overcoming it.